[Mode of preparation of labile blood products--available products].
LABILE BLOOD PRODUCTS: Labile blood products are therapeutic products produced from blood which do not have the characteristics of drugs. This category of products include packed red cells, platelets as well as white cell concentrates and frozen fresh plasma. PACKED RED CELLS AND PLATELET CONCENTRATES: These products used to be prepared from total blood. Specific components can be selected using a cell separator (apheresis). This process has made available platelet apheresis products, white cell concentrates and fresh plasma for therapeutic indications. The major impact of apheresis on blood donation has been to reduce the number of donors required for platelet transfusion. PLASMA: In France, plasma is produced from total blood by fractionation in order to assure the production of blood-derived drugs (albumin, coagulation factors, immunoglobulins, biological glue...). Viral inactivation concerns only detergent solvant viro-inactivated plasma. No therapeutic process has been fully validated for other labile blood products. TRANSFORMATION AND CHARACTERISTICS: Labile blood products may undergo several types of transformation: deplasmatization, plasma volume reduction, cyropreservation, irradiation. Since April 1, 1998, all labile cellular blood products produced in France must be leukocyte-depleted. Additional donor-related characterization (phenotype, CMV negative) may also be determined.